Fatty liver disease medication may have no effect

Jan 13, 2009

A new randomized, prospective trial has shown that orlistat, a commonly prescribed inhibitor of fat absorption, does not help patients with fatty liver disease (FLD) lose weight, nor does it improve their liver enzymes or insulin resistance. These findings are in the January issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD).

With obesity on the rise throughout the world, FLD has become a major epidemic. Weight loss improves liver enzymes and levels of fat in the liver, and the study did show that patients who lost 5 percent or more of their body weight over nine months did experience these improvements.

However, since it is often difficult for people to lose weight through diet and exercise, researchers have looked for medications that could help. Many studies have focused on orlistat, which is sold as the brand-name Xenical and over-the-counter as Alli.

Researchers led by Stephen A. Harrison, a U.S. Army hepatologist, conducted a randomized, controlled trial of overweight patients with FLD to determine the effect of orlistat in conjunction with caloric restriction. They included 50 people who had been diagnosed with FLD after clinical evaluation and liver biopsy. For 36 weeks, all subjects followed a diet of 1400 calories per day, a multivitamin and vitamin E regimen and were randomized to take orlistat (120 mg orally, three times per day with meals).

After 36 weeks, patients underwent a liver biopsy and the researchers looked for improvement in fat levels and fibrosis score. They also monitored changes in biochemical data such as fasting insulin and glucose, liver enzymes, lipid panel vitamin E and free fatty acid levels.

"Comparing the orlistat group to the non-orlistat group at study completion, no significant differences were identified between the two groups for mean weight loss, serum, insulin resistance or cholesterol," the authors report. In addition, there were no significant differences in the liver biopsy findings.

Because there were no notable differences between the two groups, the researchers reanalyzed the data to compare subjects who lost differing amounts of body weight. They noted a linear relationship between weight loss and liver improvement. In fact, body weight loss of 9 percent or more resulted in the greatest amount of liver improvement.

"In conclusion, while this preliminary study does not demonstrate a weight loss advantage with the use of orlistat," the authors report, "it does demonstrate that moderate weight loss is associated with significant improvements in the symptoms of FLD."

Article: "Orlistat for Overweight Subjects with Nonalcoholic Steatohepatitis (NASH): A Randomized, Prospective Trial." Harrison, Stephen; Fecht, William; Brunt, Elizabeth; Neuschwander-Tetri, Brent. Hepatology ; January 2009.

Source: Wiley

Explore further: FDA OKs Cubist antibiotic for serious infections

add to favorites email to friend print save as pdf

Related Stories

Extreme BMI cause for concern in liver transplantation

Aug 04, 2009

A recent study by doctors at the University of Washington explained that patients who are significantly underweight or very severely obese prior to liver transplantation are at increased risk of death following transplantation ...

The genome of sesame sheds new lights on oil biosynthesis

Mar 07, 2014

Researchers from Oil Crops Research Institute of the Chinese Academy of Agricultural Sciences, BGI, University of Copenhagen and other institutes have successfully cracked the genome of high oil content crop sesame, providing ...

Recommended for you

FDA OKs Cubist antibiotic for serious infections

14 hours ago

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.